Task-Specific Dystonia is a predominant disorder of Top-Down Sensorimotor integration
Objective: In this study we investigate two neurophysiologic variables testing for central-peripheral and peripheral-central mechanisms of SM integration in a cohort of TSD to evaluate…Network Localisation of Multiple System Atrophy
Objective: To apply a novel neuroimaging method, Coordinate-based Network Mapping (CNM)1, to localise heterogeneous neuroimaging findings in multiple system atrophy (MSA) into a functionally connected…Cycling Deep Brain Stimulation for Parkinson’s Disease
Objective: To compare gait disorders in patients with Parkinson's disease (PD) and Deep Brain Stimulation (DBS) using continuous vs cycling (40sec on, 2sec off) stimulation.…Deep brain stimulation increases descending inhibitory control in a patient with Parkinson´s disease and pain
Objective: We present the first observation of deep brain stimulation (DBS) effects on spinal nociception as assessed by the nociceptive flection reflex (NFR) during DBS…Challenging diagnosis of familial Gerstmann-Straussler-Scheinker disease with normal brain image: a case report and systematic review
Objective: We report a case of familial Gerstmann-Straussler-Scheinker (GSS) disease, who presented with cerebellar ataxia, but did not show abnormalities in diffusion weighted image (DWI)…Protective effects of Hibiscus sabdariffa extracts in 6-hydroxydopamine-lesioned parkinsonism.
Objective: The therapeutic effects of Hibiscus sabdariffa (HS) were investigated in parkinsonism rats induced by 6-hydroxydopamine (6-OHDA). Background: The oxidative stress is an important component…Association of glucocerebrosidase genotype and disease progression in early Parkinson’s disease over the course of 80 weeks
Objective: *Background and objectiveWe conducted post-hoc analyses with data of the Levodopa in EArly Parkinson’s disease (LEAP) study to compare the rate ofdisease progression in…Beta-agonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies
Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of beta-agonist and the risk of PD.…Safety of opicapone after 5 years of post-marketing experience worldwide
Objective: To review the safety data of opicapone (OPC) after five years of marketing experience worldwide Background: OPC is a once-daily catechol-O-methyltransferase (COMT) inhibitor proven…OCEAN Study in Parkinson’s Disease: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone
Objective: This study aims to evaluate if treatment with opicapone (OPC) 50 mg once-daily can improve motor fluctuation (MF)-related pain in patients with Parkinson’s disease…
- « Previous Page
- 1
- …
- 95
- 96
- 97
- 98
- 99
- …
- 153
- Next Page »